8^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance March 08-09, 2021 Rome, Italy

After a successful conference of Antibiotics 2020, we are currently bringing forth “8^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2021) slated on March 08-09, 2021 | Webinar. Antibiotics 2021 aims to gather attendees, participants, students, and speakers, organizing committee members, delegates, most elegant societies and industries, renowned and honourable persons from top universities across the globe to this webinar event. We are delighted to invite you to our 8^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance on March 08-09, 2021.

Antibiotics 2021 covers various aspects of Antibiotics, Antimicrobial Therapy, Antimicrobial Peptides, Antibiotics for Emerging & Re-Emerging Diseases, Drug Discovery Technologies in Antibiotics, Antibiotic production and Delivery method, Microorganisms Producing Antibiotics, Applications of Antibiotics, Pharmacokinetics and Pharmacodynamics of Antimicrobial drugs, Veterinary Importance of Antibiotics, Antibiotics for Oncology, Antibiotics Overuse and Resistance, Antibiotic-resistant Bacterial infections, Mechanism and Evolution of Antibiotic Resistance, Genetics of Antibiotic Resistance, Clinical Trials of Antibiotics, Clinical and Economic Burden of Antibiotic Resistance, Antibiotics: Market Analysis & Business Opportunities, Prevention and Control of Antibiotic resistance, New antibiotics and non-antibiotic approaches, Current research in antibiotic resistance, The Next Generation Approach of Antibiotics, Developing Alternatives to Antibiotics.

Track 1: COVID-19 AND ANTIBIOTIC RESISTANCE

The coronavirus COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War Two. During the current COVID-19 pandemic there are potential threats that could affect antimicrobial stewardship activities and drive antimicrobial resistance. The use of antibiotics in people with COVID-19 could result in increased resistance to the drugs' benefits among the wider population. Patients hospitalized as a result of the virus are being given a combination of medications to prevent possible secondary bacterial infections.

Antibiotics underpin all of modern medicine, but AMR is an issue that could impact millions of lives in the decades to come. Currently, the COVID-19 pandemic is causing immense suffering and loss of life across the globe, but AMR has been and will remain one of the most significant threats to global human health.

• COVID-19
• AMR
• Antibiotics
• Antimicrobial stewardship

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 2: MRSA

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a form of contagious bacterial infection. People sometimes call it a superbug because it is resistant to numerous antibiotics. In healthy people, MRSA does not usually cause a severe infection, but older people, individuals with health conditions, and those with a weakened immune system may be at risk. MRSA is a common and potentially serious infection that has developed resistance to several types of antibiotics. These include methicillin and related antibiotics, such as Penicillin, Vancomycin, and Oxacillin. This resistance makes MRSA difficult to treat.

Most MRSA infections occur in people who've been in hospitals or other health care settings, such as nursing homes and dialysis centers. When it occurs in these settings, it's known as health care-associated MRSA (HA-MRSA). HA-MRSA infections typically are associated with invasive procedures or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection has occurred in the wider community among healthy people. This form, community-associated MRSA (CA-MRSA), often begins as a painful skin boil. It's spread by skin-to-skin contact.

• MRSA
• Health care-Associated MRSA (HA-MRSA)
• Community-Associated MRSA (CA-MRSA)
• Sepsis
• Pneumonia

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 3: ANTIBIOTICS

Antibiotics are a type of antimicrobials used in treatment and prevention of bacterial infections. They may inhibit or kill the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to animals and humans also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as influenza or common cold, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

• Antibiotics Classification
• Antibiotics Types
• Side effects of antibiotics
• Antibiotic Drug interactions
• Antibiotic Tests and Treatment

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 4: VACCINES AND IMMUNIZATION

Immunization is a global health and development success story, saving millions of lives every year. Vaccines reduce risks of getting a disease by working with your body’s natural defences to build protection. When you get a vaccine, your immune system responds. We now have vaccines to prevent more than 20 life-threatening diseases, helping people of all ages live longer, healthier lives. Immunization currently prevents 2-3 million deaths every year from diseases like Diphtheria, Tetanus, Pertussis, Influenza and Measles.

Immunization is a key component of primary health care and an indisputable human right. It’s also one of the best health investments money can buy. Vaccines are also critical to the prevention and control of infectious-disease outbreaks. They underpin global health security and will be a vital tool in the battle against antimicrobial resistance.

• Vaccines
• Immunization
• Poliomyelitis (Polio)
• Tetanus
• Measles
• Influenza

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 5: INFECTIOUS DISEASES

Infectious Diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. Infectious diseases may be of water borne, food borne, vector borne, air borne in human beings as well as in plants and animals. Infectious diseases basically emphasize on the pathogenesis of the bacteria and their therapeutic measures, coalesce of branches of Microbiology especially Clinical and Diagnostic Microbiology which deals with the cure and prevention of the Infectious diseases. It represents an increasingly important cause of human morbidity and mortality throughout the world. Vaccine development is thus of great importance in terms of global health.

Corona Virus disease

Bacterial Infections Diseases

Viral Infectious Diseases

Mycobacterial Infections

Reproductive Infectious Diseases

Sexually Transmitted Diseases

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 6: ANTIMICROBIAL THERAPY

An antimicrobial therapy kills or inhibits the growth of microorganisms such as bacteria, fungi, or protozoans. Antimicrobial agents are some of the most widely, and often used therapeutic drugs worldwide. It contributes significantly to the quality of life of many people and reduces the morbidity and mortality due to infectious disease. The remarkable success of antimicrobial therapy has been achieved with comparatively little toxicity and expense.

• Antimicrobial agents
• Use of Antimicrobial Combinations
• Pharmacodynamics Characteristics
• Efficacy at the Site of Infection
• Common Misuses of Antibiotics

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 7: ANTIMICROBIAL PEPTIDES

Antimicrobial peptides (AMPs), also called Host Defence Peptides (HDPs) are part of the innate immune response found among all classes of life. AMPs have a broad spectrum of targeted organisms ranging from viruses to parasites. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as Immunomodulatory.

• Structure and Major Activities of AMPs
• Major Categories of AMPs
• Mechanism of Action of AMPs
• New Targets of AMPs
• Resistance to Antimicrobial Peptides

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 8: ANTIBIOTICS FOR EMERGING & RE-EMERGING DISEASES

Antimicrobial agents play vital roles in decreasing human morbidity and mortality resulting from infectious diseases. Emerging and re-emerging infectious diseases are global problems, and a constant supply of new antibiotics is essential if we are to combat these diseases successfully. The session is open to discuss on synthetic tailoring, discovery of new scaffolds, designing screens that avoid rediscovering old scaffolds, repurposing libraries of synthetic molecules for use as antibiotics, Exploring microbial niches for products, molecular target selection, improving libraries to overcome resistance, Safety and efficacy, Vaccines available for the diseases, Phage’s and parasitic bacteria, Epidemiology and spread of microbes and resistance traits.

• Antimicrobial resistance (AMR)
• Emerging infectious diseases
• Reemerging infectious diseases
• Emergence of Antimicrobial Resistance
• Mechanisms of Antimicrobial Resistance

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 9: DRUG DISCOVERY TECHNOLOGIES IN ANTIBIOTICS

Infectious diseases account for nearly one fifth of the worldwide death toll every year. The constant increase of drug‐resistant pathogens is a big challenge for treatment of infectious diseases. In addition, outbreaks of infections and new pathogens are potential threats to public health. Lack of effective treatments for drug‐resistant bacteria and recent outbreaks of Ebola and Zika viral infections have become a global public health concern. The number of newly approved antibiotics has decreased significantly in the last two decades compared with previous decades. In parallel with this, is an increase in the number of drug‐resistant bacteria. For these threats and challenges to be countered, new strategies and technology platforms are critically needed. Drug remodelling has emerged as an approach for rapid identification of effective therapeutics to treat the infectious diseases.

• Drug Discovery Technologies
• Applications to exploit actinomycetes as a resource for new antibiotics
• Antimicrobials by immune stimulation
• Molecular and functional genomic approaches to novel antibacterial target discovery
• Improved microbial identification

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

 Track 10: ANTIBIOTIC PRODUCTION AND DELIVERY METHOD

Antibiotic production can be grouped into three methods: natural fermentation, semi-synthetic, and synthetic. As more and more bacteria continue to develop resistance to currently produced antibiotics, research and development of new antibiotics continues to be important. In addition to research and development into the production of new antibiotics, repackaging delivery systems is important to improving efficacy of the antibiotics that are currently produced. Improvements to this field have seen the ability to add antibiotics directly into implanted devices, aerosolization of antibiotics for direct delivery, and combination of antibiotics with non-antibiotics to improve outcomes.

• Identifying useful Antibiotics
• Industrial production techniques
• Strains used for the production
• Aerosolization
• Meropenem

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 11: MICROORGANISMS PRODUCING ANTIBIOTICS

Antibiotic is one of the most important commercially exploited secondary metabolites produced by bacteria, fungi and Streptomyces and employed in a wide range. Most of the antibiotics used today are from the microorganisms that live in soil. Bacteria are easy to isolate, culture, maintain and to improve their strain. The main producers of the microbial metabolites, the actinobacteria, fungi and other filamentous bacteria, represent inexhaustible sources for the future.

• Acremonium chrysogenum
• Streptomyces hygroscopicus
• Streptomyces erythreus
• Streptomyces griseus
• Streptomyces aureofaciens
• Streptomyces orientalis

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 12: APPLICATIONS OF ANTIBIOTICS

Antibiotics are used commercially, potentially useful in medicine for activities other than their antimicrobial action. They are used as antitumor agents, enzyme inhibitors including powerful hypocholesterolemic agents, immunosuppressive agents, and anti-migraine agents, etc. This session mainly is to focus on the application of anti-bacterials, antifungals, and anti-cancers with their clinical use to date, including the development history, side effects, and etc. The antibiotics were classified by their uses, structure types, and molecular mechanisms.

• Antitumor antibiotics
• Food preservative antibiotics
• Antibiotics as veterinary medicine
• Antibiotics for control of plant diseases
• Antibiotics as tools in molecular biology

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 13: PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIMICROBIAL DRUGS

The pharmacodynamics of an antimicrobial drug relates its pharmacokinetics to the time course of the antimicrobial effects at the site of the infection. Knowledge of the drug's antimicrobial pharmacodynamics effects provides a more rational basis for determination of optimal dosing regimens in terms of the dose and the dosing interval than do the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) determined in vitro. This session mainly focus on pharmacokinetics, antimicrobial pharmacodynamics, the effect of pharmacodynamics on the emergence of resistant bacterial subpopulations, and the development of pharmacodynamics breakpoints for use in the design of trials of these drugs and in the treatment of infected patients.

• Pharmacokinetics
• Pharmacodynamics
• Antimicrobial susceptibility
• Concentration-dependent antimicrobial activity
• Time-dependent antimicrobial activity

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 14: VETERINARY IMPORTANCE OF ANTIBIOTICS

Antibiotics are used in livestock production for two basic reasons: disease treatment and disease prevention. Just like humans, animals are prone to bacterial infections. As in human medicine, antibiotics are used to effectively treat those infections. In livestock production, antibiotics can also be used to prevent disease. There are times in an animal’s life, such as weaning, where certain diseases can be very common. Antibiotics are sometimes used to prevent these diseases from becoming established in the first place.

• Aminoglycosides
• Beta Lactam Antibiotics
• Chloramphenicol
• Diaminopyrimidines (Trimethoprim)
• Glycopeptides

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 15: ANTIBIOTICS FOR ONCOLOGY

An antibiotic is a chemical made by a microbe that antagonizes the growth of other cells.  They reduce the viability and clonal expansion of cancer stem cells is of broad importance, as cancer stem cells are increasingly accepted as a distinct cell type that gives rise to therapy resistance, tumour recurrence and distant metastasis. Therapeutic anticancer antibiotics have become an accepted treatment for certain types of cancer. These drugs bind specifically to primary and metastatic cancer cells to block cell growth, while limiting effects on surrounding healthy cells. Antibiotic medicines kill malignant cells by fragmenting the DNA in the cell nucleus and by oxidizing critical compounds which are necessary for the cell. Antibiotics are used against leukaemia, bladder cancer, testicular cancer, and sarcomas.

• Chemotherapy antibiotics
• Anti-tumour antibiotics
• Cancer Immunotherapy
• Antibiotic prophylaxis

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 16: ANTIBIOTICS OVERUSE AND RESISTANCE

Antibiotic overuse is when antibiotics are used when they're not needed. Antibiotics are one of the great advances in medicine. But overprescribing them has led to resistant bacteria (bacteria that are harder to treat). Some germs that were once very responsive to antibiotics have become more and more resistant. Antibiotic overuse is a key driver of antimicrobial resistance. Antibiotic resistance occurs when bacteria change in response to the use of these medicines. Antibiotic resistance occurs naturally, but misuse of antibiotics in humans and animals is accelerating the process. Antibiotic resistance leads to longer hospital stays, higher medical costs and increased mortality.

• Overuse and overprescribing of antibiotics
• Antibiotic resistance
• Superbugs and Super resistance
• Risks of antibiotic over usage
• Prevention and control

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 17: ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS

Antibiotics have been used to treat people with infectious diseases caused by bacteria. However, certain antibiotics have been used so widely and for so long that some bacteria that cause disease have become resistant to them, making these treatments less effective. Antibiotic resistance occurs when the medication loses its ability to kill bacteria. As a result, the organisms continue to grow and cause infection, even in the presence of the antibiotic.

• Antibiotic Resistant Bacteria
• Multidrug-resistant bacteria
• Methicillin-Resistant Staphylococcus Aureus
• Streptococcus Pneumoniae
• Carbapenem-Resistant Enterobacteriaceae

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 18: MECHANISM AND EVOLUTION OF ANTIBIOTIC RESISTANCE

Antibiotics target essential cellular functions but bacteria can become resistant by acquiring either exogenous resistance genes or chromosomal mutations. Resistance mutations typically occur in genes encoding essential functions; these mutations are therefore generally detrimental in the absence of drugs. However, bacteria can reduce this handicap by acquiring additional mutations, known as compensatory mutations. Genetic interactions (epistasis) either with the background or between resistances (in multiresistant bacteria) dramatically affect the fitness cost of antibiotic resistance and its compensation, therefore shaping dissemination of antibiotic resistance mutations.

• Enzymatic degradation of antibacterial drugs
• Alteration of bacterial proteins
• Changes in membrane permeability to antibiotics
• Exogenous resistance genes
• Chromosomal mutations
• Epistasis

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 19: GENETICS OF ANTIBIOTIC RESISTANCE

Acquired bacterial antibiotic resistance can result from the mutation of normal cellular genes, the acquisition of foreign resistance genes, or a combination of these two mechanisms. The most common resistance mechanisms employed by bacteria include enzymatic degradation or alteration of the antimicrobial, mutation in the antimicrobial target site, decreased cell wall permeability to antimicrobials, and active efflux of the antimicrobial across the cell membrane. The spread of mobile genetic elements such as plasmids, transposons, and integrons has greatly contributed to the rapid dissemination of antimicrobial resistance among several bacterial genera of human and veterinary importance.

• Antibiotic resistance genes
• Horizontal genetic transfers
• Multidrug-resistant genes
• Resistance-nodulation-division
• β-lactamases

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021 

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 20: CLINICAL TRIALS OF ANTIBIOTICS

There has been an increasing use of antibiotics in all areas of medicine. Clinical trials to test antibiotics are normally of a less than satisfactory quality. The main objective of initial clinical trials, at least, is to provide the pharmaceutical company with sufficient information to persuade the regulatory authority that the drug is effective, safe and well produced.

• Factors in the Designing the antibiotics
• Genomic screening and information technology
• Randomized clinical trials
• Phases of clinical trials
• Interpretation of the clinical trials
• Drug Evaluation         

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 21: CLINICAL AND ECONOMIC BURDEN OF ANTIBIOTIC RESISTANCE

Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behaviour in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. This session mainly focus on variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance.

• Antibiotic Resistance
• Economic Analysis
• Healthcare associated infections
• Outcomes
• Study design

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021 

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 22: ANTIBIOTICS: MARKET ANALYSIS & BUSINESS OPPORTUNITIES

Antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings. Pharmaceutical companies are actively developing analogues of existing antibiotic classes based on innovative approaches to fight bacterial infections. Key players operating in the global antibiotic market include Pfizer Inc., Astellas Pharma, Inc, Roche, Novartis AG, Bristol-Myers Squibb Co., Bayer HealthCare AG, Abbott Laboratories, MiddleBrook Pharmaceuticals, Takeda Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Eli Lilly and Co., and Kyorin Pharmaceutical Co., Ltd. The antibiotics market was valued at USD 39.8 billion in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products.

• Antibiotics Market analysis
• Business Opportunities
• Key market trends
• Competitive Landscape
• Major players

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 23: PREVENTION AND CONTROL OF ANTIBIOTIC RESISTANCE       

Antimicrobial resistance is a complex problem with many diverse contributing factors. It is major cause of health concerns adding cost to oneself and to the community, directly or indirectly. Prevention is still the best tool to reduce the infection spread and thereby AMR. Along with rational use of existing antimicrobial drugs, development of new effective compounds and new diagnostic technology is the need. Joint efforts from patients, prescribers and individuals to international regulators and policy makers are needed to fight against the globally spreading antimicrobial resistance.

• International Measures
• National Strategies
• Action at Community Level
• Rational use of antibiotics
• Good Microbiology Practices

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021 

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 24: NEW ANTIBIOTICS AND NON-ANTIBIOTIC APPROACHES

New antibiotics need to be developed, which doctors will be able to use when existing drugs no longer work. Non-antibiotic treatments can also reduce our dependence on antibiotics. The government encourages companies to develop new drugs and treatments. New technologies can also help prevent infections.

• Research collaboration on antibiotic resistance
• Development of new antibiotics
• Non-antibiotic approaches
• New health technologies

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 25: CURRENT RESEARCH IN ANTIBIOTIC RESISTANCE

Antibiotic overuse and misuse has led to a growing number of bacteria in humans, animals and the environment that are resistant to life-saving antimicrobial therapies. Urgent action is needed to halt the development of resistance, and to accelerate new treatments for bacterial infection. Research includes epidemiology of both Gram-negative and Gram-positive infections, genetic mechanisms of resistance, evolution and transmission in the hospital setting, as well as the community, and antimicrobial stewardship.

• Novel antibacterial drug discovery
• Investigating antibiotic use
• Determining minimal-risk policies
• Nutrition as a method of controlling bacterial infections
• Economic implications of bacterial resistance

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021   

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 26: THE NEXT GENERATION APPROACH OF ANTIBIOTICS

As research into antibiotic resistance expands, it is important to adopt an explicitly proactive approach to antibiotic resistance identification and surveillance, as well as antibiotic therapy development. This proactive approach involves using a combination of functional metagenomics, next-generation sequencing and cutting-edge computational methods to monitor the evolution and dissemination of resistance before a given resistance determinant emerges in a pathogen or in the clinical setting, as well as proactively developing next-generation therapies that target these resistance determinants. Recent advances in the field highlight the promise that the next generation of resistome studies hold for characterizing and countering emerging resistance threats.

• Next-Generation Sequencing (NGS)
• Functional metagenomics
• Cutting-edge computational methods
• Next-generation surveillance
• Next-generation therapeutics

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021  

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Track 27: DEVELOPING ALTERNATIVES TO ANTIBIOTICS

Alternatives to antibiotics are broadly defined as any substance that can be substituted for therapeutic drugs that are increasingly becoming ineffective against pathogenic bacteria due to antimicrobial resistance. Although antibiotics remain an essential tool for treating animal diseases on the farm, the availability of effective medical interventions to prevent and control animal diseases is one of the most significant challenges facing veterinary medicine in the 21st century. Phytochemicals as antibiotic alternatives to promote growth and enhance host health. Innovative drugs, chemicals, and enzymes within the animal production chain. Vaccines as alternatives to antibiotics for food producing animals. Also recent research provides numerous possibilities for the application nanomaterials in broad-spectrum eradication of pathogenic bacteria with many applications such as skin pathogen infection, implant sterilization, and wastewater treatment.

• Alternatives to Antibiotics
• Phytochemicals
• Nanomaterials
• Antibiotic Growth Promoters (AGPs)
• Plant secondary compounds

Related Conferences: Antibiotics March 08-09, 2021 | Pharmaceutica March 15-16, 2021 | Chromatography  March 15-16, 2021 | Materials Chemistry March 26-27, 2021 | Euro Biosimilars  April 28-29, 2021 | Pharma Europe 2021, April 28-29, 2021 | Industrial Chemistry May  24-25, 2021 | Pharmaceutical Sciences June 16-17, 2021 | Natural Products June 16-17, 2021 | Euro Chemistry June 21-22, 2021 | Medicinal Chemistry July 07-08, 2021 | Mass Spectra July 07-08, 2021 | Organic Chemistry July 26-27, 2021 |Pain Management August 02-03, 2021 | Pharmacology  August 16-17, 2021 | Environmental Chemistry  September 08-09, 2021 | Physical Chemistry  September 13-14, 2021 | Pharmacovigilance September 15-16, 2021 | Formulations September 15-16, 2021 | Separation Techniques  October 22-23, 2021 | Pharma Chemistry  October 25-26, 2021 | Clinical Research  November 15-16, 2021 

Related Societies:

Societies in USA:

Alliance for the Prudent Use of Antibiotics (APUA), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Transatlantic task force on urgent antimicrobial resistance (TATFAR), Global Antibiotic Resistance Partnership (GARP), Center for a Livable Future (CLF), Infectious Diseases Society of America

Societies in Europe:

The World Alliance Against Antibiotic Resistance (WAAAR), Antibiotic Research UK (ANTRUK), BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance), ReAct – Action on Antibiotics, Compassion in World Farming (CIWF)

Societies in Asia and Pacific:

Australian Society of Antimicrobials, Australasian Society for Infectious Diseases, The Philippine Society for Microbiology, Israel Society for Microbiology (ISM), Chinese Society for Microbiology (CSM), Iranian Society of Microbiology

Antibiotics 2021 Market Analysis

The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%.The Antibacterial Drugs market is expected to cross US$ 38 Billion by 2024 growing at a CAGR of 1% during the given forecast period. Rising pervasiveness of irresistible illnesses particularly in creating locales, for example, Asia Pacific and MEA is foreseen to contribute towards showcase development.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players include Allergen plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. Novartis AG, Pfizer, Inc., and Sanofi.

The antibiotics market generated sales of US$42 billion in 2009 globally, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global pharmaceutical market. However, the antibiotics market is maturing; it showed an average annual growth of 4% over the past 5 years, compared with a growth of 16.7% and of 16.4% for antiviral drugs and vaccines, respectively.

Over 15.0% of the passing’s, in kids underneath the age of five, are assessed to be because of pneumonia and as indicated by the insights given by the WHO around 9.2 million passing’s were recorded in 2015. Like tuberculosis, the most elevated commonness of the sickness is recognized to be in the South Asian and Sub-Saharan locales. At present, the required anti-infection treatment is accessible just to 33% of the tainted populace, subsequently expanding the illness trouble.

The major driving factors of Antibacterial Drugs Market are as follows:

• There is a very high prevalence of infectious diseases.
• The research and development activities have increased.
• Product differentiation through various methods.
• Increased government support.

The restraining factors of Antibacterial drugs Market is as follows:

• Rise in drug resistant species.
• Launch of the generic drugs.
• Patent expiry

Importance and Scope

Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.

Where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. Similarly, in countries without standard treatment guidelines, antibiotics are often over-prescribed by health workers and veterinarians and over-used by the public. Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.

Target Audience

• Healthcare Students, Scientists, and professors
• Doctors
• Microbiologist
• Infectious diseases specialists
• Antimicrobial scientists
• Pharmacists
• Public health experts
• Laboratorist
• Bacteriology Researchers
• Faculty of bacteriology and infectious diseases
• Medical Colleges
• Healthcare Associations and Societies
• Business Entrepreneurs

Related Companies

1. Gilead Sciences
2. Pfizer
3. Abbott Laboratories
4. Merck & Co
5. Eli Lilly
6. Astellas Pharma
7. Teva Pharmaceutical Industries
8. Boehringer Ingelheim
9. Roche
10. Mylan
11. 3-D Matrix
12. Agilent
13. BeiGene
14. BioDuro
15. Fosun Pharma

Related Associations and Societies 

1. World Health Organization
2. U.S. Food and Drug Administration (FDA)
3. Natural Resources Defense Council (NRDC)
4. Infectious Diseases Society of America
5. World Health Assembly
6. Center for a Livable Future (CLF)
7. The Humane Society of the United States (HSUS)
8. Alliance for the Prudent Use of Antibiotics
9. Civil Society Organisations
10. British Society for Antimicrobial Chemotherapy
11. Pediatric Infectious Diseases Society
12. Royal Society of Medicine
13. European Society of Clinical Microbiology and Infectious Diseases
14. CAESAR (Central Asian & Eastern European Surveillance of Antimicrobial Resistance)
15. WAAAR - World Alliance Against Antibiotic Resistance
16. ReAct – Action on Antibiotic Resistance
17. American Medical Association